TABLE 93Deterministic and PSA results for the manufacturer's base case and new base case with corrected beta distributions (350 runs)

ADDeterministicStochastic
Cost (£)QALYsICER (£)Cost (£)QALYsICER (£) (95% CI)
Mild
Base-case model−33860.147−22,975−17860.130−13,764 (−18,873 to −8768)
New base-case model−35630.164−21,713−31660.156−20,282 (−22,837 to −17,730)
Moderate
Base-case model−18830.109−17,310−13160.105−12,585 (−17,728 to −7553)
New base-case model−17630.111−15,824−13800.109−12,678 (−15,309 to −10,057)

From: 5, Assessment of industry submissions to NICE

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.